Cargando…

A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients

BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing...

Descripción completa

Detalles Bibliográficos
Autores principales: Foucher, Yohann, Lorent, Marine, Tessier, Philippe, Supiot, Stéphane, Sébille, Véronique, Dantan, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836440/
https://www.ncbi.nlm.nih.gov/pubmed/29506537
http://dx.doi.org/10.1186/s12955-018-0870-6
_version_ 1783303968564183040
author Foucher, Yohann
Lorent, Marine
Tessier, Philippe
Supiot, Stéphane
Sébille, Véronique
Dantan, Etienne
author_facet Foucher, Yohann
Lorent, Marine
Tessier, Philippe
Supiot, Stéphane
Sébille, Véronique
Dantan, Etienne
author_sort Foucher, Yohann
collection PubMed
description BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing disease progression but with a substantial deterioration of their Health-Related Quality of Life (HRQoL). Therefore, it seems relevant to compare the treatments by considering both survival and HRQoL. In this mini-review, the aim was to question whether the potential trade-offs between survival and HRQoL are considered in high impact factor journals. METHODS: The study was conducted from the PubMed database for recent papers published between May 01, 2013, and May 01, 2015. We also restricted our search to nine medical journals with 2013 impact factor > 15. RESULTS: Among the 30 selected studies, only six collected individual HRQoL as a secondary endpoint by using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. In four studies, the time to HRQoL change was analyzed, but its definitions varied. In two studies, the mean changes in HRQoL between the baseline and the 12- or 16-week follow-up were analyzed. None of the six studies reported in a single endpoint both the quantity and the quality of life. CONCLUSIONS: Our mini-review, which only focused on recent publications in journals with high-impact, suggests moving PC clinical research towards patient-centered outcomes-based studies. This may help physicians to propose the most appropriate treatment on behalf of patients. We recommend the use of indicators such as Quality-Adjusted Life-Years (QALYs) as principal endpoint in future clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-018-0870-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5836440
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58364402018-03-07 A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients Foucher, Yohann Lorent, Marine Tessier, Philippe Supiot, Stéphane Sébille, Véronique Dantan, Etienne Health Qual Life Outcomes Review BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing disease progression but with a substantial deterioration of their Health-Related Quality of Life (HRQoL). Therefore, it seems relevant to compare the treatments by considering both survival and HRQoL. In this mini-review, the aim was to question whether the potential trade-offs between survival and HRQoL are considered in high impact factor journals. METHODS: The study was conducted from the PubMed database for recent papers published between May 01, 2013, and May 01, 2015. We also restricted our search to nine medical journals with 2013 impact factor > 15. RESULTS: Among the 30 selected studies, only six collected individual HRQoL as a secondary endpoint by using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. In four studies, the time to HRQoL change was analyzed, but its definitions varied. In two studies, the mean changes in HRQoL between the baseline and the 12- or 16-week follow-up were analyzed. None of the six studies reported in a single endpoint both the quantity and the quality of life. CONCLUSIONS: Our mini-review, which only focused on recent publications in journals with high-impact, suggests moving PC clinical research towards patient-centered outcomes-based studies. This may help physicians to propose the most appropriate treatment on behalf of patients. We recommend the use of indicators such as Quality-Adjusted Life-Years (QALYs) as principal endpoint in future clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-018-0870-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-05 /pmc/articles/PMC5836440/ /pubmed/29506537 http://dx.doi.org/10.1186/s12955-018-0870-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Foucher, Yohann
Lorent, Marine
Tessier, Philippe
Supiot, Stéphane
Sébille, Véronique
Dantan, Etienne
A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
title A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
title_full A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
title_fullStr A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
title_full_unstemmed A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
title_short A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
title_sort mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836440/
https://www.ncbi.nlm.nih.gov/pubmed/29506537
http://dx.doi.org/10.1186/s12955-018-0870-6
work_keys_str_mv AT foucheryohann aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT lorentmarine aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT tessierphilippe aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT supiotstephane aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT sebilleveronique aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT dantanetienne aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT foucheryohann minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT lorentmarine minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT tessierphilippe minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT supiotstephane minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT sebilleveronique minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients
AT dantanetienne minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients